Segment Information (Tables)

12 Months Ended

Sep. 29, 2017

Segment Reporting Information [Line Items]

Revenue for Each Operating Segment

	Revenues
	Fiscal Years
(In millions)	2017		2016		2015
Oncology Systems:
Product	$	1,383.0	$	1,430.3	$	1,359.2
Service	1,102.7		1,027.7		987.6
Total Oncology Systems	2,485.7		2,458.0		2,346.8
Varian Particle Therapy:
Product	172.5		153.1		137.9
Service	10.0		9.5		5.6
Total Varian Particle Therapy	182.5		162.6		143.5
Total reportable segments	2,668.2		2,620.6		2,490.3
Other	—		0.5		0.4
Total Company	$	2,668.2	$	2,621.1	$	2,490.7

Operating Earnings for Each Operating Segment

	Operating Earnings
	Fiscal Years
(In millions)	2017			2016			2015
Oncology Systems	$	520.7		$	518.6		$	447.4
Varian Particle Therapy	(95.7		)	(44.6		)	(26.5		)
Total reportable segments	425.0			474.0			420.9
Other	—			(5.6		)	(6.2		)
Corporate	(83.1		)	(33.4		)	(19.0		)
Total Company	$	341.9		$	435.0		$	395.7

Depreciation and Amortization and Total Assets for Each Operating Segment

	Depreciation & Amortization						Total Assets
	Fiscal Years						Fiscal Years
(In millions)	2017		2016		2015		2017		2016		2015
Oncology Systems	$	39.4	$	28.5	$	21.8	$	1,452.7	$	1,491.2	$	1,411.3
Varian Particle Therapy	6.1		6.8		4.8		354.4		367.8		294.0
Total reportable segments	45.5		35.3		26.6		1,807.1		1,859.0		1,705.3
Other	—		0.2		0.2		—		2.1		2.2
Corporate	24.8		28.3		28.5		1,361.2		1,325.2		1,275.9
Discontinued operations	6.6		16.0		13.2		11.1		628.5		595.3
Total Company	$	76.9	$	79.8	$	68.5	$	3,179.4	$	3,814.8	$	3,578.7

Revenues and Property, Plant and Equipment by Geographic Basis

Geographic Information

	Revenues						Property, plant and equipment, net
	Fiscal Years						Fiscal Years
(In millions)	2017		2016		2015		2017		2016		2015
United States	$	1,237.0	$	1,161.7	$	1,212.3	$	163.8	$	177.0	$	194.8
International	1,431.2		1,459.4		1,278.4		91.5		81.6		78.3
Total Company	$	2,668.2	$	2,621.1	$	2,490.7	$	255.3	$	258.6	$	273.1

Continuing Operations

Segment Reporting Information [Line Items]

Operating Earnings for Each Operating Segment

The reconciliation of segment operating earnings (losses) to the Company’s earnings from continuing operations before taxes was as follows:

	Fiscal Years
(In millions)	2017			2016			2015
Oncology Systems	$	520.7		$	518.6		$	447.4
Varian Particle Therapy	(95.7		)	(44.6		)	(26.5		)
Total reportable segments	425.0			474.0			420.9
Other	—			(5.6		)	(6.2		)
Corporate	(83.1		)	(33.4		)	(19.0		)
Interest income, net	2.9			5.6			5.6
Total earnings from continuing operations before taxes	$	344.8		$	440.6		$	401.3